NEURON BIO, S.A. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| - EUR | -.--% |
|
-.--% | -.--% |
| 2017 | Neuron BioLabs, S.L. cancelled the acquisition of diagnostics operations, R&D services and patents of Alzheimer's disease from Neuron Bio, SA. | CI |
| 2017 | Neol Biosolutions Seeks Investors | CI |
| Sales 2015 | 1.21M 1.32M | Sales 2016 | 2.59M 2.81M | Capitalization | 13.76M 14.92M |
|---|---|---|---|---|---|
| Net income 2015 | - 0 | Net income 2016 | -2M -2.17M | EV / Sales 2015 | 23.8 x |
| Net Debt 2015 | 17.66M 19.16M | Net Debt 2016 | 17.5M 18.98M | EV / Sales 2016 | 12.1 x |
| P/E ratio 2015 |
128
x | P/E ratio 2016 |
-5.92
x | Employees | - |
| Yield 2015 * |
-
| Yield 2016 |
-
| Free-Float | 86.92% |
More Fundamentals
* Assessed data
More news
| Managers | Title | Age | Since |
|---|---|---|---|
| Director of Finance/CFO | - | - | |
| Corporate Officer/Principal | 57 | - | |
| Corporate Secretary | 67 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Founder | 79 | 05-12-18 | |
| Director/Board Member | 67 | - | |
| Director/Board Member | - | - |
Neuron BioPharma SA is a Spain-based company engaged in the biotechnology sector. The Company is active in the discovery and development of pharmaceutical compounds aimed at the prevention and treatment of various neurodegenerative diseases, with a main focus in the research on Alzheimer's disease. The Company operates also in three platforms: Drug Discovery, Pre-clinical development and Clinical development.
| 1st Jan change | Capi. | |
|---|---|---|
| -.--% | 5.19M | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B | |
| +77.64% | 8.87B |
- Stock Market
- Equities
- NEU Stock
